BioCryst Pharmaceuticals, Inc.

414 articles with BioCryst Pharmaceuticals, Inc.

• BioCryst to Present at 22nd Annual H.C. Wainwright Global Investment Conference - Sep 08, 2020

  9/8/2020

  BioCryst Pharmaceuticals, Inc. announced that the company will present at the 22nd annual H.C. Wainwright Global Investment Conference on Monday, September 14, 2020 at 9:30 a.m. ET.

• U.S. Government Exercises Option To Purchase Additional RAPIVAB® from BioCryst for Delivery to Strategic National Stockpile

  9/3/2020

  BioCryst Pharmaceuticals, Inc. announced that the U.S. Department of Health and Human Services has exercised its option to purchase an additional 10,000 doses of BioCryst’s approved antiviral influenza therapy, RAPIVAB®, for approximately $7 million.

• BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 03, 2020

  9/3/2020

  BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 22 newly-hired employees inducement options to purchase an aggregate of 333,000 shares of BioCryst common stock on August 31, 2020 as inducements material to each employee entering into employment with BioCryst.

• NIAID Awards BioCryst New $44 Million Contract to Advance Development of Galidesivir

  8/31/2020

  BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded BioCryst a new contract (75N93020C00055) totaling $44 million, and has added approximately $3 million to its existing contract (HHSN272201300017C), to support the development of galidesivir.   The additional funds under these performance-base

• FDA Grants Orphan Drug Designation for BCX9930 in PNH

  8/31/2020

  BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug designation for its oral Factor D inhibitor, BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria.

• BioCryst Reports Second Quarter 2020 Financial Results and Upcoming Key Milestones

  8/6/2020

  —ORLADEYO ™ (berotralstat) approvals expected in U.S. and Japan in Q4 2020, EU in early 2021— —200 mg/400mg BCX9930 data from treatment-naïve PNH patients expected in Q3 2020, 200 mg/400mg data from poor-responders to C5 inhibitors expected by year end 2020 — —Information from Part 1 of galidesivir trial in COVID-19 patients expected by end of Q3 2020—                                                                       RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2020 (GLOBE NE

• BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 04, 2020

  8/4/2020

  BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 20 newly-hired employees inducement options to purchase an aggregate of 290,000 shares of BioCryst common stock on July 31, 2020 as inducements material to each employee entering into employment with BioCryst.

• FDA Grants Fast Track Designation for BCX9930 in PNH

  8/3/2020

  BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation for its oral Factor D inhibitor, BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria.

• BioCryst to Report Second Quarter 2020 Financial Results on August 6

  7/23/2020

  BioCryst Pharmaceuticals, Inc. announced that the company will report its second quarter 2020 financial results on Thursday, August 6, 2020.

• BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 02, 2020

  7/2/2020

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 70,000 shares of BioCryst common stock on June 30, 2020 as inducements material to each employee entering into employment with BioCryst.

• Galidesivir Stops Zika Viral Replication in Primate Model

  6/10/2020

  BioCryst Pharmaceuticals, Inc. announced new data published in Science Translational Medicine show, in a primate model, that galidesivir was safe, provided post-exposure prevention of Zika viral replication across a range of doses, and rapidly reduced viral loads to undetectable levels when dosed up to 72 hours after infection with Zika virus.

• BioCryst Announces Berotralstat Expanded Access Program for Patients with Hereditary Angioedema in United States

  6/9/2020

  BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has established an expanded access program (EAP) with oral, once-daily berotralstat, an investigational drug, for patients with hereditary angioedema (HAE) in the United States.

• Hereditary Angioedema Patients Report Breakthrough Attacks on Current Injectable/Infused Prophylaxis Medication

  6/6/2020

  Data presented at European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress

• BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 02, 2020

  6/2/2020

  BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 147,500 shares of BioCryst common stock on May 29, 2020 as inducements material to each employee entering into employment with BioCryst.

• BioCryst Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock and Pre-Funded Warrants

  6/1/2020

  BioCryst Pharmaceuticals, Inc. announced the completion of an underwritten public offering of 22,044,447 shares of its common stock, including 3,333,334 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares, and of pre-funded warrants to purchase up to an aggregate of 3,511,111 shares of common stock.

• BioCryst to Present at Jefferies Virtual Healthcare Conference

  5/28/2020

  BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 10:30 a.m. ET.

• BioCryst Prices Public Offering of Common Stock and Pre-Funded Warrants

  5/28/2020

  BioCryst Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 18,711,113 shares of its common stock, offered at a price to the public of $4.50 per share.

• BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants

  5/27/2020

  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today that it is offering to sell $100 million of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock in an underwritten public offering.

• BioCryst to Present New Berotralstat Data at European Academy of Allergy and Clinical Immunology Digital Congress

  5/26/2020

  BioCryst Pharmaceuticals, Inc. announced that the company will present new data on berotralstat, an oral, once-daily therapy under regulatory review in the United States, Japan and the European Union for the prevention of hereditary angioedema attacks, at the upcoming digital congress of the European Academy of Allergy and Clinical Immunology June 6-8.

• BioCryst Celebrates HAE Patients with HAE Global Walk

  5/15/2020

  BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced companywide activities in support of hae day :-) 2020, a global awareness day for hereditary angioedema (HAE). BioCryst stands in solidarity with the HAE community by participating in the annual HAE Global Walk. Since actual community walks cannot currently be organized, BioCryst employees around the world are joining virtually with others supporting hae day :-) b